Premium
MiMedx Group Inc (MDXG)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key prod... MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties. Show more
Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs’ Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024...
MARIETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the...
Net Sales of $84 million Grew 3% Year-Over-Year for the Third QuarterThird Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, RespectivelyThird Quarter Adjusted EBITDA was...
MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the...
MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for...
Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research MARIETTA, Ga., Oct...
EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.76 | 23.6559139785 | 7.44 | 9.32 | 7.325 | 1607325 | 8.64842723 | CS |
| 4 | 3.33 | 56.7291311755 | 5.87 | 9.32 | 5.585 | 908693 | 7.53748507 | CS |
| 12 | 2.55 | 38.3458646617 | 6.65 | 9.32 | 5.47 | 684045 | 6.80011353 | CS |
| 26 | 1.2 | 15 | 8 | 9.32 | 5.47 | 673086 | 6.90889932 | CS |
| 52 | 2.55 | 38.3458646617 | 6.65 | 9.32 | 5.47 | 719374 | 7.34569274 | CS |
| 156 | 1.08 | 13.3004926108 | 8.12 | 9.32 | 2.43 | 638803 | 5.90090669 | CS |
| 260 | 5.54 | 151.366120219 | 3.66 | 15.99 | 2.43 | 682814 | 6.93743671 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
